Institut National de la Santé Et de la Recherche Médicale, France
972
145
194
545
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.1%
79 terminated/withdrawn out of 972 trials
87.3%
+0.8% vs industry average
6%
58 trials in Phase 3/4
3%
18 of 545 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (972)
Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease
Role: lead
French Childhood Cancer Survivor Study
Role: lead
LEOPARD Prospective Validation Cohort 1
Role: collaborator
COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival
Role: collaborator
Synaptic Plasticity Imaging With Diffusion MRI
Role: lead
Molecular Characterization for Understanding Biliary Atresia
Role: lead
Compare the Intensity of Pain Felt by Children During the Local Anesthesia Procedure to That Perceived by the Accompanying Parent.
Role: collaborator
Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia
Role: lead
Myeloid Cells in Patients With Covid-19 Pneumonia
Role: collaborator
Developpement of 3T MRI Protocol
Role: lead
Combined tDCS+PNS After Acute Stroke
Role: lead
Genetic Susceptibility to Radiation Induced Thyroid Cancer
Role: lead
Deep Brain Stimulation for Patients With Parkinson's Disease.
Role: lead
Multimodal Study of the Human Brain Epilepsy Tissue
Role: collaborator
Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes
Role: lead
Neopterin on Admission to Intensive Care Unit
Role: collaborator
Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)
Role: lead
Study of Cognitive and Behavioural Biases in People With Idiopathic Environmental Intolerance (IEI) Versus Healthy Controls
Role: lead
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
Role: lead
Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers
Role: collaborator